SLNO
Price:
$56.14
Market Cap:
$2.18B
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.[Read more]
Industry
Biotechnology
IPO Date
2014-11-13
Stock Exchange
NASDAQ
Ticker
SLNO
According to Soleno Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.13B. This represents a change of 87.39% compared to the average of 1.13B of the last 4 quarters.
The mean historical Enterprise Value of Soleno Therapeutics, Inc. over the last ten years is 68.79M. The current 2.13B Enterprise Value has changed 308.87% with respect to the historical average. Over the past ten years (40 quarters), SLNO's Enterprise Value was at its highest in in the June 2024 quarter at 1.58B. The Enterprise Value was at its lowest in in the March 2022 quarter at -10682100.00.
Average
68.79M
Median
11.90M
Minimum
-5960378.30
Maximum
494.52M
Discovering the peaks and valleys of Soleno Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 22.59%
Maximum Annual Enterprise Value = 494.52M
Minimum Annual Increase = -1459.14%
Minimum Annual Enterprise Value = -5960378.30
Year | Enterprise Value | Change |
---|---|---|
2023 | 494.52M | 22.59% |
2022 | 2.18M | -81.62% |
2021 | 11.86M | -83.48% |
2020 | 71.77M | -10.23% |
2019 | 79.95M | 526.13% |
2018 | 12.77M | -1459.14% |
2017 | -939494.00 | -109.55% |
2016 | 9.84M | -17.65% |
2015 | 11.94M | -300.38% |
2014 | -5960378.30 | -132.82% |
The current Enterprise Value of Soleno Therapeutics, Inc. (SLNO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
169.52M
5-year avg
132.06M
10-year avg
68.79M
Soleno Therapeutics, Inc.’s Enterprise Value is greater than Annexon, Inc. (621.99M), greater than Icosavax, Inc. (713.87M), greater than VectivBio Holding AG (848.58M), greater than Bolt Biotherapeutics, Inc. (38.25M), greater than Lyra Therapeutics, Inc. (22.05M), greater than Pulmatrix, Inc. (-6183620.00), greater than Capricor Therapeutics, Inc. (839.91M), greater than Akari Therapeutics, Plc (26.33M), greater than Diffusion Pharmaceuticals Inc. (-1447403.00), greater than Onconova Therapeutics, Inc. (4.51M), greater than Catalyst Biosciences, Inc. (19.42M), greater than Bio-Path Holdings, Inc. (-340985.00), greater than Moleculin Biotech, Inc. (-3343901.00), greater than Day One Biopharmaceuticals, Inc. (1.07B), greater than Acumen Pharmaceuticals, Inc. (137.49M), greater than X4 Pharmaceuticals, Inc. (20.60M), greater than Inozyme Pharma, Inc. (308.76M), greater than Applied Molecular Transport Inc. (-5743713.00), greater than Aileron Therapeutics, Inc. (64.72M), greater than Benitec Biopharma Inc. (163.42M),
Company | Enterprise Value | Market cap |
---|---|---|
621.99M | $749.09M | |
713.87M | $769.04M | |
848.58M | $1.06B | |
38.25M | $25.56M | |
22.05M | $17.21M | |
-6183620.00 | $7.59M | |
839.91M | $845.38M | |
26.33M | $29.50M | |
-1447403.00 | $8.98M | |
4.51M | $20.90M | |
19.42M | $19.42M | |
-340985.00 | $3.61M | |
-3343901.00 | $6.97M | |
1.07B | $1.49B | |
137.49M | $177.24M | |
20.60M | $89.59M | |
308.76M | $277.29M | |
-5743713.00 | $11.01M | |
64.72M | $86.66M | |
163.42M | $214.00M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Soleno Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Soleno Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Soleno Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Soleno Therapeutics, Inc. (SLNO)?
What is the 3-year average Enterprise Value for Soleno Therapeutics, Inc. (SLNO)?
What is the 5-year average Enterprise Value for Soleno Therapeutics, Inc. (SLNO)?
How does the current Enterprise Value for Soleno Therapeutics, Inc. (SLNO) compare to its historical average?